Update shared on05 Sep 2025
As both the future P/E and revenue growth forecasts for Max Healthcare Institute remained essentially unchanged, analysts have left their fair value estimate steady at ₹1252.
What's in the News
- Board approved entering into an Agreement to Lease with Goyal Agrim Infra Realty LLP to set up a 130-bed hospital in Dehradun, Uttarakhand on a built-to-suit basis, with Goyal Agrim responsible for construction and furnishing.
- Max Healthcare to provide milestone-linked, interest-free deposits and bear costs like stamp duty; total expected outflow is approximately INR 300 million.
- Initial lease term agreed for 29 years, with provision for renewal for another 29 years; lease rent to be finalized based on development cost and built-up area.
- Board meeting scheduled to approve unaudited standalone and consolidated financial results for the quarter ended June 30, 2025, and to consider the Dehradun hospital agreement.
- Appointment of M/s. S.R. Batliboi & Co. LLP as Statutory Auditor approved at the Annual General Meeting.
Valuation Changes
Summary of Valuation Changes for Max Healthcare Institute
- The Consensus Analyst Price Target remained effectively unchanged, at ₹1252.
- The Future P/E for Max Healthcare Institute remained effectively unchanged, moving only marginally from 54.37x to 54.31x.
- The Consensus Revenue Growth forecasts for Max Healthcare Institute remained effectively unchanged, at 29.9% per annum.
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.